Suchergebnisse - "Bullano, Michael"

PubPharm (58)

1

Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy : A US-based study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2024

von Schultz, B. | Bullano, M. | Paratane, D. | +1

2

Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy : A US‐based study

enthalten in: Transplant Infectious Disease | 2024

von Schultz, B. | Bullano, M. | Paratane, D. | +1

3

A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors

enthalten in: Expert review of hematology | 2023

von Escobar, M. | Bullano, M. | Mokdad, A. | +4

4

Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States : A real-world comparative analysis

enthalten in: Journal of managed care & specialty pharmacy | 2023

von Xing, S. | Batt, K. | Kuharic, M. | +5

5

Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States : Demographics, clinical characteristics and costs

enthalten in: Haemophilia : the official journal of the World Federation of Hemophilia | 2023

von Batt, K. | Xing, S. | Kuharic, M. | +5

ErratumIn: Haemophilia. 2024 Mar 5;:. - PMID 38444109

6

Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A

enthalten in: Expert review of pharmacoeconomics & outcomes research | 2023

von Bullano, M. | Cool, C. | Schultz, B. | +5

7

Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors

enthalten in: Journal of medical economics | 2023

von Escobar, M. | Agrawal, N. | Chatterjee, S. | +4

8

Re : Response letter to Sanofi's communication related to "the budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States"

enthalten in: Journal of medical economics | 2023

von Farahbakhshian, S. | Inocencio, T. | Poorman, G. | +3

CommentOn: J Med Econ. 2022 Jan-Dec;25(1):755-761. - PMID 35611840

9

Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data

enthalten in: Journal of medical economics | 2023

von Farahbakhshian, S. | Fan, Q. | Schultz, B. | +3

10

A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab

enthalten in: Current medical research and opinion | 2022

von Batt, K. | Schultz, B. | Caicedo, J. | +4

1
2
3
4
5
6
Nächster »
[6]